Fundraising Tips From The Top Of European Biotech
Zoom And Teams Have Expanded Access To Backers
The biotech sector is awash with capital and the rise of the virtual roadshow is breaking down geographic barriers, giving European firms a better chance to impress US investors.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: pharma’s Q2 prospects; Bayer’s plans for the US launch of its CKD drug; big tobacco takes further steps into healthcare; KRAS’s emergence in oncology amid ongoing challenges; and tips for European biotech fundraising.
Interview: Germany’s ITM is executing on its plan to develop targeted radionuclide-based therapies with its lead lutetium-177 product in Phase III trials supported by a just closed $109m financing.
Following positive interim results from a Phase I/IIa trial of BI-1206 in combination with Roche's Rituxan, BioInvent has raised a significant sum to push the non-Hodgkin's lymphoma drug towards late-stage development.